Recently, two clinical trials showed that, among patients with T1DM and in T2DM treated with insulin (and with at least one hypoglycemia risk factor), the Deg treatment resulted in a reduced rate of overall symptomatic hypoglycemia, as compared to Glar-100 [34, 35]. The gene discussed is INS; the disease is Hypoglycemia.